Keros Therapeutics Inc (KROS) Q4 2025 Earnings Call Transcript

Why It Matters

The imminent Phase III readouts could unlock a multi‑billion‑dollar myelofibrosis market and reshape Karyopharm's cash outlook, making financing decisions pivotal for investors.

Key Takeaways

• Q4 revenue $34.1M, 11.8% YoY growth.
• XPOVIO drives $32.1M quarterly product revenue.
• Cash runway extends only into Q2 2026.
• Phase III SENTRY data expected March 2026.
• 2026 revenue guidance $130‑150M, expense $230‑245M.

Pulse Analysis

Karyopharm Therapeutics’ latest earnings reveal a modest top‑line rebound anchored by XPOVIO, its flagship oral XPO1 inhibitor. Total revenue rose to $34.1 million in the fourth quarter, while disciplined cost cuts trimmed R&D spend by 17% and SG&A by 16% year‑over‑year. Despite these improvements, the company posted a GAAP net loss exceeding $100 million and its cash position fell to $64 million, shortening the cash runway to the second quarter of 2026. This financial backdrop underscores the urgency of securing additional capital as the firm navigates a pivotal growth phase.

The clinical pipeline is the engine driving Karyopharm’s future valuation. The Phase III SENTRY trial, evaluating selinexor plus ruxolitinib in frontline myelofibrosis, is set to release topline data in March 2026. Early Phase I results showed a 79% SVR35 rate and an 18.5‑point TSS improvement, far surpassing historical JAK‑inhibitor benchmarks. A successful readout could validate a market opportunity that the company estimates could approach $1 billion annually in the United States. Simultaneously, the EXPORT EC042 trial targets p53‑wild‑type endometrial cancer, with mid‑2026 data expected to broaden the franchise beyond hematologic indications.

Strategically, Karyopharm’s 2026 guidance projects total revenue of $130‑$150 million, largely powered by XPOVIO, while forecasting combined R&D and SG&A expenses of $230‑$245 million. The mismatch between projected spend and cash resources signals that financing—whether through equity, debt, or strategic partnerships—will be a critical agenda item for the board. Investors will be watching the Phase III outcomes closely, as positive data could catalyze a re‑rating, improve cash flow prospects, and justify the anticipated expense ramp. Conversely, any delay or negative result may intensify dilution risk and pressure the company’s valuation in a competitive oncology market.